NCT02609230 A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma Status COMPLETED Phase PHASE1
NCT02583165 A Study in Adult Subjects With Select Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02578316 A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. Status COMPLETED Phase PHASE1
NCT02565758 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02564900 Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Status COMPLETED Phase PHASE1
NCT02561455 Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial Status COMPLETED Phase PHASE1/PHASE2
NCT02551185 ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02546531 Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Status COMPLETED Phase PHASE1
NCT02526017 Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Status COMPLETED Phase PHASE1
NCT02516813 Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Status COMPLETED Phase PHASE1
NCT02462707 A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors Status WITHDRAWN Phase PHASE1
NCT02460224 Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Status COMPLETED Phase PHASE1/PHASE2
NCT02456883 Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02454972 Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Status COMPLETED Phase PHASE2
NCT02442414 A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02432326 A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02367352 Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors Status TERMINATED Phase PHASE1